Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Influenza B Virus Strain For 2004-2005 To Be Confirmed In March

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA committee recommends switch from a Victoria to a Yamagata lineage influenza B strain. For influenza A, New Caledonia (H1N1) strain will be retained, while a Fujian-like strain will replace this season's Panama-like strain.

You may also be interested in...



Influenza Vaccine Provides Protection Despite Drifted Strains, CDC Says

An adult case-control study found that influenza vaccine may still provide "substantial health benefit" despite a suboptimal match between circulating and vaccine strains. The Centers for Disease Control & Prevention is planning to conduct two pediatric prospective flu vaccine studies for the 2004-2005 season.

Influenza Vaccine Provides Protection Despite Drifted Strains, CDC Says

An adult case-control study found that influenza vaccine may still provide "substantial health benefit" despite a suboptimal match between circulating and vaccine strains. The Centers for Disease Control & Prevention is planning to conduct two pediatric prospective flu vaccine studies for the 2004-2005 season.

Influenza B Vaccine Strain Confirmed By FDA Committee

A Yamagata lineage strain should replace a Victoria lineage strain in the 2004-2005 vaccine, the committee says.

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel